Latest News

 

Zogenix Viewpoints

 

Technology

04-24-14 Zogenix Announces Sale of SUMAVEL(R) DosePro(R) Migraine Therapy to Endo International
04-24-14 A Common Sense Approach to Appropriate Drug Use
04-23-14 Zogenix Responds to Governor's Action Singling Out Zohydro™ ER in Massachusetts, Encourages Officials to Consider Patient Needs and Effective Class-Wide Measures

 

Latest Entries:

  • Let's Get the Facts Straight About Zohydro ER--and the Important Patient Need It Fills (April 11, 2014)

    Rampant misinformation about Zohydro™ ER continues to be reported by the media and echoed in Washington D.C. and some states' capitals. These inaccurate and misleading statements are often made without proper context, and are intended to be sensational, to create fear, or to generate headlines. In many instances, these statements are not supported by scientific facts or medical evidence.

  • FDA, HHS Reaffirm Support for Chronic Pain Patients Amid Zohydro ER Debate (April 3, 2014)

    Yesterday, Health and Human Services (HHS) Secretary Kathleen Sebelius, and U.S. Food and Drug Administration (FDA) Commissioner Dr. Margaret Hamburg, called for a balanced approach in the fight against prescription drug abuse and preserving the protection of the needs and rights of patients suffering from severe chronic pain. It was an impressive showcase of a unified front and a call for all stakeholders to help at every level.

  • Let's Get the Facts Straight About Zohydro ER (April 2, 2014)

    We are extremely disappointed that the U.S. Drug Enforcement Administration (DEA) Administrator, as she did in a Congressional hearing today, would repeat misinformation about Zohydro™ ER that has been demonstrated to be false.

  • Massachusetts Denies Patients a Legitimate Option for Severe Chronic Pain (March 27, 2014)

    We agree with Governor Deval Patrick's intention to curb the epidemic of drug abuse in Massachusetts. However, we are extremely concerned by his unprecedented action with respect to a specific FDA-approved prescription medication.

  • Message from Zogenix CEO Roger Hawley to Stakeholders (March 20, 2014)

    An increasing number of news reports have been including false and misleading statements about our company and our product, Zohydro™ ER (hydrocodone bitartrate) extended-release capsules (CII), the first and only extended release hydrocodone product without acetaminophen.

  • FDA Commissioner Hamburg Reiterates the Necessity of Zohydro ER (March 18, 2014)

    Zogenix is committed to ensuring the safe, effective and responsible treatment of chronic pain patients. Zohydro ER (hydrocodone bitartrate) extended-release capsules, is the first available extended release hydrocodone product without acetaminophen for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, and was approved by the U.S. Food and Drug Administration (FDA) after an extended, 18-month, comprehensive review process.

  • Our commitment to responsibly manage, distribute and commercialize Zohydro ER (March 14, 2014)

    Zohydro ER (hydrocodone bitartrate) Extended Release Capsules, CII, were approved by the Food and Drug Administration (FDA) on October 25, 2013, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

  DosePro is a first-in-class, easy-to-use drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle. DosePro offers benefits to patients including instant, easy dosing, less anxiety over self-injection, no need for sharps disposal, no risk of needle stick injury or contamination, and reliable performance.